BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
A total of 300 new bisphosphonates were screened for their effect on bone resorption in the rat. Among these, 1-hydroxy-3-(methylpentylamino)propylidenebisphosphonate (BM 21.0955) was selected for detailed investigation. It inhibited arotinoid-stimulated bone resorption as assessed by calcemia in thyroparathyroidectomized rats at a SC dose as low as 0.001 mg P (0.016 mumol) per kg body weight per day. The compound was thus about 2, 10, 50, and 500 times more potent than risedronate, alendronate, pamidronate, and clodronate, respectively. Intravenous administration was as effective as subcutaneous, and oral administration was 100 times less effective. The effect after one administration decreased with time but was still measurable after 2 weeks. Nonstimulated bone resorption assayed by the urinary excretion of radiolabeled tetracycline from lifelong prelabeled animals was also inhibited. This effect started 3 days after a single dose and was still maximal after 7 days. Histomorphometric analysis of the tibial metaphysis in growing intact rats also showed an inhibition of bone resorption along with an increase in bone mass. The number of osteoclasts increased in animals treated with 0.01 and 0.1 mg P per kg (0.16 and 1.6 mumol/kg) body weight SC but decreased in animals given 1 mg P per kg (16.1 mumol/kg), showing that the inhibition of bone resorption was not due to an inhibition of osteoclast recruitment. No inhibition of mineralization occurred. This new bisphosphonate appears to have great potential for use in human bone disease.
Mühlbauer
R C
RC
Department of Pathophysiology, University of Berne, Switzerland.
Bauss
F
F
Schenk
R
R
Janner
M
M
Bosies
E
E
Strein
K
K
Fleisch
H
H
D019386:Alendronate; D000818:Animals; D001565:Benzoates / Q000494:pharmacology; D001862:Bone Resorption / Q000517:prevention & control*; D002118:Calcium / Q000097:blood* / Q000378:metabolism; D004002:Clodronic Acid / Q000494:pharmacology; D004164:Diphosphonates / Q000008:administration & dosage / Q000138:chemical synthesis / Q000494:pharmacology*; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D000077557:Ibandronic Acid; D007275:Injections, Intravenous; D010010:Osteoclasts / Q000187:drug effects* / Q000378:metabolism; D000077268:Pamidronate; D051381:Rats; D012176:Retinoids / Q000494:pharmacology; D000068296:Risedronic Acid; D013054:Spectrophotometry, Atomic; D013752:Tetracycline / Q000737:chemistry / Q000652:urine; D013974:Thyroxine / Q000494:pharmacology
D001565:Benzoates; D004164:Diphosphonates; D012176:Retinoids; D004002:Clodronic Acid; C034814:ethyl-p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)-1-propenyl)benzoic acid; D013752:Tetracycline; D000068296:Risedronic Acid; D012968:Etidronic Acid; D000077268:Pamidronate; D013974:Thyroxine; D002118:Calcium; D000077557:Ibandronic Acid; D019386:Alendronate